Trial Profile
A Study to Examine the Potential Effect of Rifampin on the Pharmacokinetics of Neratinib When Administered Concomitantly to Healthy Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 19 May 2012
Price :
$35
*
At a glance
- Drugs Neratinib (Primary) ; Rifampicin
- Indications Advanced breast cancer; Early breast cancer; Non-small cell lung cancer; Solid tumours; Tuberculosis
- Focus Pharmacokinetics
- Sponsors Wyeth
- 11 May 2012 Additional company (Puma Biotechnology) added in association as reported by ClinicalTrials.gov.
- 11 May 2012 Planned initiation date changed from 1 May 2009 to 1 Apr 2009 as reported by ClinicalTrials.gov.
- 16 Jun 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.